AP-SA02

About Innoviva

Innoviva operates a dual-strategy business model, generating significant royalty revenue from its legacy respiratory assets partnered with GlaxoSmithKline (GSK), including TRELEGY ELLIPTA, ANORO ELLIPTA, and RELVAR/BREO ELLIPTA. This financial foundation supports its development of a diversified pipeline in areas of high unmet need, such as oncology and infectious diseases, through subsidiaries like Innoviva Specialty Therapeutics. The company's strategic focus is on acquiring and advancing late-stage clinical assets with the potential for near-term commercialization.

About Armata Pharmaceuticals

Armata Pharmaceuticals is focused on addressing the global antibiotic resistance crisis through its precision bacteriophage therapeutics, aiming to preserve the healthy human microbiome. The company has built a robust, in-house platform for phage discovery, engineering, and manufacturing, supporting a pipeline targeting multi-drug resistant pathogens like Pseudomonas aeruginosa and Staphylococcus aureus. Led by a seasoned team, including former White House Coronavirus Task Force coordinator Dr. Deborah Birx as CEO, Armata is positioning itself as a leader in the emerging phage therapy space.

Therapeutic Areas